Closing Thoughts: Optimism, Responsibility, and the Path Forward for BCMA-Targeted Therapy in Multiple Myeloma

In the final episode, 'Closing Thoughts: Optimism, Responsibility, and the Path Forward for BCMA-Targeted Therapy in Multiple Myeloma,' the panelists explored the following critical question:

What are your final takeaways from today's discussion?

Zahra Mahmoudjafari expressed optimism about the remarkable evolution of multiple myeloma management over her career while acknowledging the significant responsibility that accompanies the expanding therapeutic landscape, emphasizing the need for operational infrastructure that ensures appropriate access, continued advocacy around Risk Evaluation and Mitigation Strategy (REMS) programs, and strong cross-specialty partnerships such as those with ophthalmology that are critical to safely delivering agents like belantamab mafodotin. Al-Ola Abdallah echoed these sentiments, underscoring that the ultimate obligation of every clinician is to ensure patients receive the best available treatment regardless of barriers, and called on academic centers to actively engage community oncologists by sharing resources, contacts, and education given that multiple myeloma remains a rare disease with which many community practices have limited familiarity. Both panelists reinforced that pharmacists play an indispensable role in bridging these gaps, from clinical and operational expertise to patient advocacy and real-world evidence generation, and that continued collaboration between academic and community settings will be essential to ensuring that the remarkable efficacy of B-cell maturation antigen (BCMA)-directed therapies translates into improved outcomes for all patients with relapsed/refractory multiple myeloma (RRMM).

Throughout the conversation, the experts provided a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

Thank you for watching this Practice Pearls series on relapsed/refractory multiple myeloma (RRMM). Please see the Pharmacy Times website for additional educational material.